Diagnostics Solutions Strategic Priorities

Our commitment to innovation We invest more in our IVD portfolio than other companies 125 CHF million per month Roche Roche Abbott DANAHER SIEMENS 0.7 billion CHF 9% of revenue 0.5 billion CHF 1.5 billion CHF 12% of revenue 8% of revenue 0.3 billion CHF 7% of revenue R&D investments as percentage of revenue for 2019 Ref: Roche estimates for IVD portfolio based on annual reports together with independent 3rd parties (including diabetes care); Product names and trademarks are the property of their respective owners. 30

View entire presentation